Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONTRAFECT CorpCFRX · Entity 116797 | Director · Chief Executive Officer | February 15, 2022 | February 17, 2022 |
| Enlivex Ltd.ENLV · Entity 7605 | Director | March 18, 2026 | March 18, 2026 |
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director | June 10, 2025 | June 11, 2025 |
| Intec Pharma Ltd.NTEC · Entity 146542 | Director | July 15, 2020 | July 17, 2020 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | July 20, 2018 | July 23, 2018 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | June 13, 2019 | June 14, 2019 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | Director | November 25, 2024 | November 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONTRAFECT Corp
Report date February 15, 2022 · Filed February 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2032-02-15 | Direct | 500,000 |
Reported balance
After 2022-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-15 · Grant · Acquired 500,000 · Balance 500,000 F1: The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date.
Enlivex Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 0.40 per shareSEC Table I · non-derivative | Direct | 2,480 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,480 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2032-11-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The option vests ratably on an annual basis for 4 consecutive years beginning on November 17, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests ratably on an annual basis for 4 consecutive years beginning on November 17, 2023.
Indaptus Therapeutics, Inc.
Report date June 10, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2035-06-10 | Direct | 30,000 |
Reported balance
After 2025-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 30,000 · Balance 30,000 F1: The stock option vests and becomes exercisable on June 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable on June 10, 2026.
Intec Pharma Ltd.
Report date July 15, 2020 · Filed July 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-07-15 | Direct | 40,000 |
Reported balance
After 2020-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-15 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023.
Rubius Therapeutics, Inc.
Report date July 20, 2018 · Filed July 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100 |
Reported balance
After 2018-07-20 transaction · row 1
1 source rowRow 1 · 2018-07-20 · Purchase · Acquired 100 · Balance 100 |
Seres Therapeutics, Inc.
Report date June 13, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2029-06-12 | Direct | 15,000 |
Reported balance
After 2019-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-13 · Grant · Acquired 15,000 · Balance 15,000 F1: The option will vest in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders.
Viracta Therapeutics, Inc.
Report date November 25, 2024 · Filed November 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,478 |
Reported balance
After 2024-11-25 transaction · row 1
1 source rowRow 1 · 2024-11-25 · Exercise / conversion · Acquired 9,034 · Balance 126,478 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 18,069 |
Reported balance
After 2024-11-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-25 · Exercise / conversion · Disposed 9,034 · Balance 18,069 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock. F2: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
F2: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2018 Filed Jul 18, 2018 16:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $23.00 | $0.00 |
DisclosureSEC source: 0001104659-18-045777 · a4.xml · derivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-07-16 F1 · derivative.exercise_date: This option shall vest in equal quarterly installments during the twelve quarters following the grant date. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 1,010 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-019814 · doc4.xml · derivative · entry 3 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,536 Underlying: COMMON STOCK · 1,010 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 1,010 | $9.01 | $9,098.99 |
DisclosureSEC source: 0000899243-18-019814 · doc4.xml · nonDerivative · entry 2 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 1,010 | $0.71 | $717.10 |
DisclosureSEC source: 0000899243-18-019814 · doc4.xml · nonDerivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2018 Filed Jul 10, 2018 21:49 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 5,989 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-019711 · doc4.xml · derivative · entry 9 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 798,546 Underlying: COMMON STOCK · 5,989 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| July 10, 2018 Filed Jul 10, 2018 21:49 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 5,989 | $9.05 | $54,207.64 |
DisclosureSEC source: 0000899243-18-019711 · doc4.xml · nonDerivative · entry 6 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.23. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 10, 2018 Filed Jul 10, 2018 21:49 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 5,989 | $0.71 | $4,252.19 |
DisclosureSEC source: 0000899243-18-019711 · doc4.xml · nonDerivative · entry 5 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2018 Filed Jul 10, 2018 21:49 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 10,981 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-019711 · doc4.xml · derivative · entry 8 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,535 Underlying: COMMON STOCK · 10,981 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| July 09, 2018 Filed Jul 10, 2018 21:49 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 10,981 | $9.14 | $100,350.97 |
DisclosureSEC source: 0000899243-18-019711 · doc4.xml · nonDerivative · entry 4 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.35. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2018 Filed Jul 10, 2018 21:49 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 10,981 | $0.71 | $7,796.51 |
DisclosureSEC source: 0000899243-18-019711 · doc4.xml · nonDerivative · entry 3 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 21:49 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 15,366 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-019711 · doc4.xml · derivative · entry 7 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,516 Underlying: COMMON STOCK · 15,366 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 21:49 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 15,366 | $9.14 | $140,506.70 |
DisclosureSEC source: 0000899243-18-019711 · doc4.xml · nonDerivative · entry 2 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.23. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 21:49 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 15,366 | $0.71 | $10,909.86 |
DisclosureSEC source: 0000899243-18-019711 · doc4.xml · nonDerivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2018 Filed Jun 29, 2018 21:12 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 4,496 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-018742 · doc4.xml · derivative · entry 6 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,882 Underlying: COMMON STOCK · 4,496 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| June 29, 2018 Filed Jun 29, 2018 21:12 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 4,496 | $9.10 | $40,915.40 |
DisclosureSEC source: 0000899243-18-018742 · doc4.xml · nonDerivative · entry 4 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 29, 2018 Filed Jun 29, 2018 21:12 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 4,496 | $0.71 | $3,192.16 |
DisclosureSEC source: 0000899243-18-018742 · doc4.xml · nonDerivative · entry 3 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 21:12 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 21,560 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-018742 · doc4.xml · derivative · entry 5 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,378 Underlying: COMMON STOCK · 21,560 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 21:12 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 21,560 | $9.15 | $197,375.33 |
DisclosureSEC source: 0000899243-18-018742 · doc4.xml · nonDerivative · entry 2 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 21:12 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 21,560 | $0.71 | $15,307.60 |
DisclosureSEC source: 0000899243-18-018742 · doc4.xml · nonDerivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 01:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 16,991 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-018520 · doc4.xml · derivative · entry 9 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,938 Underlying: COMMON STOCK · 16,991 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 01:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 16,991 | $9.03 | $153,408.34 |
DisclosureSEC source: 0000899243-18-018520 · doc4.xml · nonDerivative · entry 6 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.16. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 01:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 16,991 | $0.71 | $12,063.61 |
DisclosureSEC source: 0000899243-18-018520 · doc4.xml · nonDerivative · entry 5 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 01:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 21,224 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-018520 · doc4.xml · derivative · entry 8 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873,929 Underlying: COMMON STOCK · 21,224 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 01:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 21,224 | $9.19 | $195,133.46 |
DisclosureSEC source: 0000899243-18-018520 · doc4.xml · nonDerivative · entry 4 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.365. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 01:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 21,224 | $0.71 | $15,069.04 |
DisclosureSEC source: 0000899243-18-018520 · doc4.xml · nonDerivative · entry 3 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2018 Filed Jun 28, 2018 01:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 16,288 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-018520 · doc4.xml · derivative · entry 7 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,153 Underlying: COMMON STOCK · 16,288 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| June 25, 2018 Filed Jun 28, 2018 01:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 26,752 | $9.21 | $246,503.63 |
DisclosureSEC source: 0000899243-18-018520 · doc4.xml · nonDerivative · entry 2 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.08 to $9.52. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 25, 2018 Filed Jun 28, 2018 01:06 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 16,288 | $0.71 | $11,564.48 |
DisclosureSEC source: 0000899243-18-018520 · doc4.xml · nonDerivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2018 Filed Jun 23, 2018 01:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 40,057 | $9.36 | $374,761.27 |
DisclosureSEC source: 0000899243-18-017794 · doc4.xml · nonDerivative · entry 3 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,768 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 21, 2018 Filed Jun 23, 2018 01:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 18,987 | $9.06 | $172,094.37 |
DisclosureSEC source: 0000899243-18-017794 · doc4.xml · nonDerivative · entry 2 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,825 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2018 Filed Jun 23, 2018 01:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 26,492 | $9.33 | $247,051.15 |
DisclosureSEC source: 0000899243-18-017794 · doc4.xml · nonDerivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,812 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2018 Filed May 10, 2018 20:44 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 233 | $9.00 | $2,097.00 |
DisclosureSEC source: 0000899243-18-012352 · doc4.xml · nonDerivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,304 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 02:03 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 278,000 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0000899243-18-002335 · doc4.xml · derivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,000 Underlying: Common Stock · 278,000 shares Expires 2028-01-29 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:39 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionStock Option (right to buy) · Derivative | 40,241 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-001894 · doc4.xml · derivative · entry 2 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911,441 Underlying: Common Stock · 40,241 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:39 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 40,241 | $0.71 | $28,571.11 |
DisclosureSEC source: 0000899243-18-001894 · doc4.xml · nonDerivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:48 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseWarrants (Right to Buy) · Derivative | 400 | $0.01 Strike: $1.55 | $4.00 |
DisclosureSEC source: 0001209191-17-046319 · doc4.xml · derivative · entry 2 Pomerantz Roger · CIK 0001614936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Common Stock, par value $0.0001 per share · 400 shares Expires 2022-07-25 Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:48 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseCommon Stock, par value $0.0001 per share | 800 | $1.24 | $992.00 |
DisclosureSEC source: 0001209191-17-046319 · doc4.xml · nonDerivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Read SEC document |
| July 18, 2017 Filed Jul 20, 2017 20:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionStock Option (right to buy) · Derivative | 100,604 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-17-018635 · doc4.xml · derivative · entry 2 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 951,682 Underlying: Common Stock · 100,604 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter. Read SEC document |
| July 18, 2017 Filed Jul 20, 2017 20:36 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 100,604 | $0.71 | $71,428.84 |
DisclosureSEC source: 0000899243-17-018635 · doc4.xml · nonDerivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 261,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0000899243-17-002120 · doc4.xml · derivative · entry 1 Pomerantz Roger · CIK 0001614936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Underlying: Common Stock · 261,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 26, 2018. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.